A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment

Trial Profile

A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Sarcoma; Uterine cancer
  • Focus Therapeutic Use
  • Acronyms HGUS Study
  • Most Recent Events

    • 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress
    • 27 Sep 2016 Data from this trial will be presented at the European Society for Medical Oncology (ESMO) 2016 Congress, reported in an Ipsen media release.
    • 18 May 2015 Planned End Date changed from 1 Jul 2017 to 1 Jul 2019 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top